Beacon Therapeutics is an ophthalmic gene therapy company founded to restore and improve the vision of patients with a range of prevalent and rare retinal diseases that result in blindness.

Our established scientific foundation combines a late-stage development candidate to treat X-linked retinitis pigmentosa (XLRP) with two innovative and differentiated preclinical programs for prevalent and rare blinding diseases.

Retinal diseases cause damage to any part of the retina at the back of the eye and can lead to severe vision loss and even blindness.

Beacon Therapeutics was launched in 2023. Find out how we are aiming to make remarkable happen.